Stock Market Reviews

Read and share opinions on CAPR (Capricor Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory
  Dec 18, 2025
• Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
  Dec 16, 2025
• How Recent Developments Are Rewriting the Story for Capricor Therapeutics
  Dec 6, 2025
• CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
  Dec 5, 2025
• Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
  Dec 5, 2025
• Capricor Therapeutics Announces Proposed Public Offering of Common Stock
  Dec 4, 2025
• Capricor Therapeutics (CAPR) Valuation After Positive Phase 3 HOPE-3 Results for DMD Therapy Deramiocel
  Dec 4, 2025
• Top Midday Gainers
  Dec 3, 2025
• Can Capricor Therapeutics' (CAPR) Exosome Advancement Shift the Conversation on Its Innovation Pipeline?
  Nov 25, 2025
• Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
  Nov 24, 2025
• Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ...
  Nov 11, 2025
• Capricor: Q3 Earnings Snapshot
  Nov 10, 2025

CAPR News

• Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory
  We came across a bearish thesis on Capricor Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on CAPR. Capricor Therapeutics, Inc.’s share was trading at $26.55 as of December 15th. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, develops transformative cell and exosome-based therapeutics for treating […]
  Dec 18, 2025
• Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
  – Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatm
  Dec 16, 2025
• How Recent Developments Are Rewriting the Story for Capricor Therapeutics
  Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to commercialization. Underpinning this upgrade are accelerated revenue growth assumptions, now closer to 156.4% versus 115.7% previously, along with a slightly higher discount rate near 7.03% that captures both the remaining risks and the richer opportunity set tied to HOPE-3 and potential priority review...
  Dec 6, 2025
• CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
  Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
  Dec 5, 2025
• Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
  SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting di
  Dec 5, 2025
• Capricor Therapeutics (CAPR) Valuation After Positive Phase 3 HOPE-3 Results for DMD Therapy Deramiocel
  Capricor Therapeutics (CAPR) just delivered positive topline data from its pivotal Phase 3 HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy, a key late stage milestone that immediately sharpens the market’s focus on this stock. See our latest analysis for Capricor Therapeutics. The HOPE-3 win arrives after a spectacular run, with a 30 day share price return of about 394 percent and a 1 year total shareholder return of roughly 136 percent. This is a clear sign that momentum is...
  Dec 4, 2025
• Capricor Therapeutics Announces Proposed Public Offering of Common Stock
  SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public
  Dec 4, 2025
• Trending tickers: Salesforce, Microsoft, Netflix, Capricor Therapeutics and Vodafone
  The latest investor updates on stocks that are trending on Thursday.
  Dec 4, 2025
• Top Midday Gainers
  Capricor Therapeutics (CAPR) shares more than quadrupled after the company said on Wednesday that a
  Dec 3, 2025
• Sector Update: Health Care Stocks Higher Wednesday Afternoon
  Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel
  Dec 3, 2025
• Sector Update: Health Care Stocks Higher Late Afternoon
  Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He
  Dec 3, 2025
• Top Midday Stories: Microsoft Lowers AI Software Sales Quotas; Marvell to Acquire Celestial AI for $3.25 Billion
  All three major US stock indexes were up in late-morning trading Wednesday, as traders largely shook
  Dec 3, 2025
• Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
  Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat
  Dec 3, 2025
• Capricor soars on positive results for Duchenne cell therapy
  Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first treatment for heart-related complications of Duchenne.
  Dec 3, 2025
• Can Capricor Therapeutics' (CAPR) Exosome Advancement Shift the Conversation on Its Innovation Pipeline?
  Capricor Therapeutics recently presented new data at the 2025 American Association for Extracellular Ventures Annual Meeting, highlighting a scalable process for loading therapeutic RNA molecules into exosomes using advanced electroporation techniques. This progress is seen as a significant step for expanding clinical manufacturing capacity, but arrives amid heightened scrutiny following regulatory setbacks and public criticism of the company’s lead therapy for Duchenne muscular dystrophy...
  Nov 25, 2025
• Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
  --Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new data describing a scalable framework for loading therapeutic small interfering RNAs (siRNA) and phosphorodiamidate morpholino oligomer
  Nov 24, 2025
• Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ...
  Capricor Therapeutics Inc (CAPR) anticipates pivotal data from its HOPE 3 trial while addressing financial hurdles and regulatory feedback.
  Nov 11, 2025
• Capricor: Q3 Earnings Snapshot
  SAN DIEGO (AP) — Capricor Therapeutics Inc. CAPR) on Monday reported a loss of $24.6 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 54 cents.
  Nov 10, 2025
• Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with Stealth
  Nov 10, 2025
• CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates
  CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of +13.95% and +3.65%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025
• Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
  –Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing cell and exosome-based therapies for rare diseases, today announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro potency assay designed to cha
  Nov 3, 2025
• We're Hopeful That Capricor Therapeutics (NASDAQ:CAPR) Will Use Its Cash Wisely
  Just because a business does not make any money, does not mean that the stock will go down. For example, although...
  Oct 31, 2025
• Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
  Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p.
  Oct 31, 2025
• Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last?
  Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Oct 30, 2025
• Capricor Therapeutics (CAPR): Evaluating Valuation After Lawsuit and FDA Decision Shake Investor Confidence
  Capricor Therapeutics (CAPR) is attracting fresh attention after a law firm began investigating potential claims on behalf of shareholders. This follows a class action lawsuit related to its lead cell therapy, deramiocel. See our latest analysis for Capricor Therapeutics. After the volatility sparked by the FDA news and ensuing legal developments, Capricor's share price roared back with a 17.6% gain over the past month, though it's still down 49% year-to-date. Long-term holders have weathered...
  Oct 10, 2025
• Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains?
  Capricor (CAPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Sep 26, 2025
• Sector Update: Health Care Stocks Slide Thursday Afternoon
  Health care stocks declined Thursday afternoon, with the NYSE Health Care Index falling 1.8% and the
  Sep 25, 2025
• Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
  FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory
  Sep 25, 2025
• Capricor readies revised FDA pitch for Duchenne cell therapy
  Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a framework that could support a clearance if upcoming study results are positive.
  Sep 25, 2025
• Capricor refutes FDA’s DMD deramiocel rejection in public statement
  Capricor released its response to the FDA publicly after the agency published its CRL for deramiocel.
  Sep 10, 2025
• Capricor Posts Response to FDA Complete Response Letter for Deramiocel
  Capricor Therapeutics (CAPR) said Tuesday it has posted the preliminary response it sent to the US F
  Sep 9, 2025
• Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
  SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement regarding the U.S. Food and Drug Administration’s (FDA) public posting of its Complete Response Letter (CRL) for the Biologics License Application (BLA) for Deramiocel, the Company’s investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dyst
  Sep 9, 2025
• Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) largest shareholders are retail investors with 58% ownership, institutions own 30%
  Key Insights The considerable ownership by retail investors in Capricor Therapeutics indicates that they collectively...
  Sep 8, 2025
• Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
  First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vac
  Aug 18, 2025
• Are Investors Undervaluing Capricor Therapeutics, Inc. (NASDAQ:CAPR) By 23%?
  NasdaqCM:CAPR 1 Year Share Price vs Fair Value Explore Capricor Therapeutics's Fair Values from the Community and...
  Aug 13, 2025
• Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...
  Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory progress to bolster future growth.
  Aug 12, 2025

CAPR Reviews

• ChartCrusher

  Dec 30, 2025

  $CAPR Another biotech with more dreams than products.

  Sell

• AlphaDecoder

  Dec 30, 2025

  $CAPR This biotechnology firm is dedicated to advancing therapeutic solutions that address unmet medical needs. Its innovative pipeline and commitment to research indicate a strong potential for breakthroughs that could impact the healthcare industry.

  Buy

• LiquidLegend

  Dec 28, 2025

  $CAPR Therapeutics that sound like the name of a rock band. Can’t wait to see them go viral, not just medicinally!

  Sell

• RiskRaider

  Dec 27, 2025

  $CAPR Therapeutics? More like a therapeutic for your patience.

  Sell

• StonkRider

  Dec 27, 2025

  $CAPR This company is at the forefront of innovative therapies that could address significant unmet medical needs, showcasing a commitment to advancing healthcare solutions.

  Buy

• QuantAssault

  Dec 27, 2025

  $CAPR If this stock were a pizza, it would definitely be loaded with the good toppings—who wouldn’t want a slice?

  Buy

• TickerFlux

  Dec 26, 2025

  $CAPR The biotech field is buzzing with excitement, and this company is right in the thick of it! Yet, the stakes are high, and investors are biting their nails over uncertainty.

  Buy

• MarketMarauder

  Dec 25, 2025

  $CAPR Promising the moon but delivering dust with no results.

  Sell

• MarketWolf

  Dec 24, 2025

  $CAPR In the relentless pursuit of innovation, this company is under immense pressure to show tangible results. Can they keep up the momentum, or will they fall behind in this fast-paced industry?

  Buy

• TheChartCode

  Dec 24, 2025

  $CAPR This company is the science fair project that actually worked, while all others just created volcanoes in the kitchen!

  Buy

• DividendVandal

  Dec 24, 2025

  $CAPR This organization is at the cutting edge of therapeutic development, focusing on unique solutions for unmet medical needs. Their commitment to research and innovation could yield promising results in the near future.

  Buy

• TradeProtocol

  Dec 23, 2025

  $CAPR If this stock was a superhero, it’d be Captain Cardio—saving lives and pumping up the profits! 🦸‍♂️💚

  Buy

• ShortKingston

  Dec 23, 2025

  $CAPR Think of it as that magical potion in a fantasy game—could be the key to something legendary or a total flop!

  Sell

• BullRunBoi

  Dec 22, 2025

  $CAPR This joint's got some serious potential, keep an eye on it!

  Buy

• CryptoCoyote

  Dec 21, 2025

  $CAPR Exciting developments are on the horizon, but will they deliver? The stakes are high, and any delay could easily derail expectations.

  Buy

• ChartFang

  Dec 21, 2025

  $CAPR This company is dedicated to advancing innovative therapies, showcasing a strong commitment to improving patient outcomes. Their focus on research and development is likely to yield fruitful advancements in the healthcare field.

  Buy

• TradeBlitz

  Dec 21, 2025

  $CAPR This company is like the kid in class who always brings snacks – everyone loves them, but can they keep it up?

  Buy

• VolatileViking

  Dec 21, 2025

  $CAPR This company is all about turning setbacks into comebacks—think of it as the ultimate underdog story you didn’t know you needed!

  Buy

• YieldVector

  Dec 21, 2025

  $CAPR With the biotech landscape full of uncertainties, this one feels like walking on a tightrope! If breakthroughs don’t come soon, it might topple!

  Sell

• BagholderElite

  Dec 20, 2025

  $CAPR This biotech's got some moves, playin' the long game for big wins!

  Buy

• WallStreetHex

  Dec 20, 2025

  $CAPR With a focus on innovative therapies in the healthcare sector, this firm presents exciting possibilities as it advances its clinical pipeline, potentially marking significant breakthroughs in treatment options.

  Buy

• RiskWraith

  Dec 20, 2025

  $CAPR Caught in a whirlwind of trials and tribulations, this company is at a crossroads. Will they find their footing or struggle to stay afloat amid the mounting pressure?

  Sell

• HODLzilla

  Dec 19, 2025

  $CAPR Watch out, this one’s sneakin’ up on the radar.

  Buy

• MarketSavage

  Dec 19, 2025

  $CAPR Therapeutics? More like therapeutic for losses.

  Sell

• BearBreaker

  Dec 19, 2025

  $CAPR Another flop masquerading as innovation.

  Sell

• TheAlphaDagger

  Dec 18, 2025

  $CAPR As clinical trials unfold, the stakes are high for this biotech firm. Will groundbreaking results propel them forward, or will they face disappointment? The anxiety is undeniable!

  Buy

• OptionOverlord

  Dec 18, 2025

  $CAPR If this biotech company were a teen, it would be the overachiever in the class—always ready to save the day with groundbreaking ideas!

  Buy

• ShortCircuit

  Dec 18, 2025

  $CAPR Therapeutics that promise to cap your hope.

  Sell

• OptionOutlaw

  Dec 16, 2025

  $CAPR A promising name that delivers nothing but disappointment.

  Sell

• TradeBlitz

  Dec 16, 2025

  $CAPR Like that friend who always has the best playlists, this one’s got a track record worth tuning into!

  Buy

• AlphaRogue

  Dec 16, 2025

  $CAPR This stock is like a superhero in the world of therapeutics—ready to save the day one innovation at a time. Capes not included!

  Buy

• OptionRogue

  Dec 16, 2025

  $CAPR Focusing on unique therapeutic solutions, this firm is addressing important unmet medical needs. Its recent advancements and clinical trials indicate promising potential for future success and expansion.

  Buy

• ProfitLancer

  Dec 16, 2025

  $CAPR More like Capricious with those results.

  Sell

• ChartPhantom

  Dec 16, 2025

  $CAPR This stock is like that friend who always has a crazy idea – sometimes they flop, but when they hit, it’s a game changer!

  Sell

• MarketDrift

  Dec 15, 2025

  $CAPR Therapeutics on deck, could be a game changer if played right!

  Buy

• YieldWarden

  Dec 15, 2025

  $CAPR Every news release feels like a rollercoaster ride—high hopes dashed or soaring optimism? The pressure is on for this biotech outfit to deliver sooner rather than later!

  Buy

• AlgoAce

  Dec 15, 2025

  $CAPR Like a superhero in disguise, this one has the potential to save the day when you least expect it. Capes not included!

  Buy

• QuantRift

  Dec 14, 2025

  $CAPR This biotechnology company is focused on developing therapies aimed at significant medical needs. The advancement of its clinical programs positions it well within the competitive biotech landscape, potentially driving future growth.

  Buy

• StockNova

  Dec 13, 2025

  $CAPR This biotech company is pioneering transformative treatments in regenerative medicine. Their recent advancements and strong pipeline indicate promising prospects for sustained growth in the healthcare sector.

  Buy

• ChartPhantom

  Dec 13, 2025

  $CAPR Momentum indicators turning green.

  Buy

• DiamondHandz

  Dec 13, 2025

  $CAPR Bullish consolidation forming.

  Buy

• Stonks4Days

  Dec 13, 2025

  $CAPR This joint’s got potential, keep your hustle on it!

  Buy

• YOLOTrader69

  Dec 12, 2025

  $CAPR Innovating like a boss, they’re on the cutting edge!

  Buy

• MarginMeme

  Dec 12, 2025

  $CAPR This looks like a classic bull trap.

  Sell

• BagholderElite

  Dec 12, 2025

  $CAPR Got some slick moves up their sleeve, keep an eye out.

  Buy

• BuyTheDipBro

  Dec 12, 2025

  $CAPR Downside expansion possible soon.

  Sell

• VolatilityViper

  Dec 11, 2025

  $CAPR Hope is not a strategy, especially not for this biotech.

  Sell

• CryptoCoyote

  Dec 11, 2025

  $CAPR With the healthcare landscape evolving, there’s immense pressure to deliver groundbreaking solutions. Are they the next big breakthrough or just another face in the crowd? Tension is mounting!

  Sell

• EquityPulse

  Dec 11, 2025

  $CAPR Strong buy zone developing.

  Buy

• AlgoAce

  Dec 11, 2025

  $CAPR Failed rally attempts continuously.

  Sell

• QuantumBroker

  Dec 11, 2025

  $CAPR Bullish catalysts lining up.

  Buy

• ChartSaber

  Dec 11, 2025

  $CAPR Massive downside risk emerging.

  Sell

• BuyLowBro

  Dec 10, 2025

  $CAPR Imagine being a superhero that makes hearts better! This stock could use a cape because it's ready to save the day!

  Buy

• TradeMatrix

  Dec 10, 2025

  $CAPR Breakthrough therapies are the talk of the town, but can this one truly deliver? With so many players in the biotech arena, every move feels like a high-stakes gamble. Investors are on edge!

  Sell

• FinTechNomad

  Dec 10, 2025

  $CAPR Innovative ideas are swirling, but time is running out! Investors are biting their nails, wondering if this company can finally transform potential into profit before the momentum fizzles out.

  Buy

• RiskRanger

  Dec 10, 2025

  $CAPR Making therapeutic breakthroughs like they're handing out free samples at the mall—who doesn't love a good deal on innovation?

  Buy

• DividendHunter

  Dec 10, 2025

  $CAPR This company is more hopeful than it ever should be.

  Sell

• FiscalEngine

  Dec 10, 2025

  $CAPR This company is making significant strides in the field of regenerative medicine, focusing on innovative therapies that could potentially address unmet medical needs. Their commitment to research and development positions them well for future advancements in healthcare.

  Buy

• PaperHandsGone

  Dec 10, 2025

  $CAPR Pushing boundaries in the health game, this crew's got some serious potential.

  Buy

• BuyLowBoi

  Dec 10, 2025

  $CAPR Biotech magic happening here, a gem waiting to explode!

  Buy

• BullRunBandit

  Dec 10, 2025

  $CAPR Sleeper hit in the making, just gotta keep it on the radar.

  Buy

• YieldWarden

  Dec 9, 2025

  $CAPR Ideal momentum environment for bulls.

  Buy

• ByteBull

  Dec 9, 2025

  $CAPR Fantastic bullish structure.

  Buy

• CandleCrusher

  Dec 9, 2025

  $CAPR Sharp bearish shift underway.

  Sell

• RiskDriver

  Dec 8, 2025

  $CAPR This company is at the forefront of innovative therapies, showcasing a commitment to addressing significant unmet medical needs. With promising advancements in their clinical pipeline, the potential for impactful growth in the biotech sector is substantial.

  Buy

• RiskProtocol

  Dec 8, 2025

  $CAPR In the world of biotech, every trial can feel like a gamble. Will this one hit the jackpot, or are investors in for a bumpy road ahead?

  Buy

• BullRunBoi

  Dec 7, 2025

  $CAPR Yo, this one’s got mad vibes, watch it blast off!

  Buy

• RiskWraith

  Dec 7, 2025

  $CAPR The tension with this stock is palpable! Just when you think you have it figured out, it throws a curveball that leaves you breathless. What a wild ride!

  Sell

• FUDCrusher

  Dec 7, 2025

  $CAPR Biotech buzz is alive, this one's got the street talkin'!

  Buy

• FiscalRiot

  Dec 7, 2025

  $CAPR It’s a high-wire act with no safety net! Each twist and turn leaves you gasping—will it find its footing or fall flat?

  Buy

• AlphaDruid

  Dec 6, 2025

  $CAPR Caught in a whirlwind of potential, this stock is either on the brink of something huge or heading toward a crash. The stakes have never felt higher!

  Buy

• MarginMarauder

  Dec 6, 2025

  $CAPR Like a puppy with a favorite toy, this stock is just waiting to fetch some serious attention!

  Buy

• BullBrawler

  Dec 5, 2025

  $CAPR A biotech dream that keeps turning into a nightmare.

  Sell

• BearFighter

  Dec 4, 2025

  $CAPR Hope is not a strategy, and neither is this stock.

  Sell

• BullRunBandit

  Dec 4, 2025

  $CAPR Bullish trend confirmation signal.

  Buy

• DividendDemon

  Dec 4, 2025

  $CAPR Higher timeframe resistance crushing price.

  Sell

• YieldSlasher

  Dec 4, 2025

  $CAPR Hope is not a strategy, yet here we are.

  Sell

• OptionOutlaw

  Dec 4, 2025

  $CAPR Strong buying interest at critical levels.

  Buy

• CashWraith

  Dec 4, 2025

  $CAPR Volume confirmation on the buy side.

  Buy

• AlphaRogue

  Dec 3, 2025

  $CAPR This one is like that underdog in a sports movie—everyone’s rooting for it, but will it finally score the winning point?

  Buy

• StonkSlayer

  Dec 2, 2025

  $CAPR This stock might just be the underdog hero in a coming-of-age movie – just waiting to surprise everyone with its epic glow-up!

  Buy

• PortfolioFreak

  Dec 2, 2025

  $CAPR The journey of this company feels like running a marathon in quicksand—struggling to gain traction while everyone waits for a breakthrough!

  Sell

• RiskRanger

  Dec 1, 2025

  $CAPR This company might have the secret sauce for turning health frowns upside down—watch out, world! Health vibes incoming!

  Buy

• RiskRanger

  Dec 1, 2025

  $CAPR Like a science experiment gone right, this one could bubble up nicely! Just hope it doesn’t explode!

  Buy

• CandleCrusher

  Nov 30, 2025

  $CAPR With all eyes on their latest developments, the pressure is mounting! Will their next move redefine the market or will it lead to another frustrating setback?

  Sell

• ShortKingston

  Nov 29, 2025

  $CAPR If this company was a superhero, its power would be transforming heartbreak into biotech magic. Let’s just hope it doesn’t get its cape stuck in a door!

  Buy

• YOLOTrader

  Nov 29, 2025

  $CAPR This company is like the superhero of therapeutics—saving the day one treatment at a time. Capes not included.

  Buy

• VolatilityViper

  Nov 28, 2025

  $CAPR Capricor is more like capricious; don't hold your breath.

  Sell

• GainsJester

  Nov 27, 2025

  $CAPR They cooking up some serious breakthroughs, watch this space heat up!

  Buy

• TheEarningsBeast

  Nov 27, 2025

  $CAPR This stock has more potential than my friend’s wild ideas for a TikTok. Watch out for those trends!

  Buy

• AlphaStriker

  Nov 27, 2025

  $CAPR Seems like a promising idea, but dreams don’t pay the bills.

  Sell

• FiscalEngine

  Nov 26, 2025

  $CAPR Focusing on breakthrough therapeutics, this company has the potential to impact its industry significantly. Their innovative pipeline may address unmet medical needs, suggesting a strong future trajectory.

  Buy

• StonkViking

  Nov 25, 2025

  $CAPR They're pushing boundaries in health tech, watch out for what's next!

  Buy

• AlphaRift

  Nov 25, 2025

  $CAPR Specializing in groundbreaking therapies, this firm is at the forefront of medical innovation. Continued advancements in its development pipeline suggest promising prospects in the healthcare sector.

  Buy

• YieldSlasher

  Nov 24, 2025

  $CAPR Innovative claims but still struggling to deliver on actual results.

  Sell

• TendieTitan

  Nov 23, 2025

  $CAPR If this stock were a superhero, it would totally be the one that saves the day with some serious science powers!

  Buy

• TendieTitan

  Nov 23, 2025

  $CAPR This one is like a superhero in a lab coat—saving the day with treatments but needs a sidekick to reach the skies!

  Sell

• GammaSlayer

  Nov 22, 2025

  $CAPR This company is like a bad gamble at a casino.

  Sell

• VolatilityCore

  Nov 21, 2025

  $CAPR With a focus on advanced therapeutic solutions, this biotechnology company is making strides that could lead to significant benefits for patients and stakeholders alike.

  Buy

• AlphaRift

  Nov 21, 2025

  $CAPR Focusing on groundbreaking therapeutic solutions, this organization demonstrates promise in addressing unmet medical needs, which could capture investor interest in the biotech arena.

  Buy

• GammaGrind

  Nov 20, 2025

  $CAPR This company got potential, keepin' the vibe strong in the biotech scene.

  Buy

• ChartPhantom

  Nov 20, 2025

  $CAPR This company is like a superhero origin story—witnessing their journey is like watching a Marvel movie unfold!

  Buy

• RiskVandal

  Nov 20, 2025

  $CAPR Therapeutics for the hopeful, but what about reality?

  Sell

• CashKiller

  Nov 20, 2025

  $CAPR A biotech that promises the moon but delivers dust.

  Sell

• CapitalCarnage

  Nov 20, 2025

  $CAPR Another health stock pretending to be a miracle.

  Sell

• CashKiller

  Nov 20, 2025

  $CAPR This one’s a rollercoaster without a safety bar.

  Sell

• DividendFrame

  Nov 19, 2025

  $CAPR Innovative solutions in biotechnology showcase this company's potential to transform healthcare. Its research-driven approach may lead to breakthroughs that resonate with both patients and investors.

  Buy

• MarketRender

  Nov 19, 2025

  $CAPR The developments in this biotech are thrilling, but with the ups and downs of clinical trials, one wrong turn could spell chaos. Are they onto something groundbreaking or just chasing shadows?

  Sell

• TheEquityEdge

  Nov 18, 2025

  $CAPR This biotech firm is pioneering new treatments that could significantly impact patient care. Its research-driven approach highlights its commitment to making a difference in healthcare, indicating strong potential for growth.

  Buy

• CashClown

  Nov 17, 2025

  $CAPR Got potential, but needs to step it up to catch some eyes.

  Sell

• MemeInvestor

  Nov 17, 2025

  $CAPR This company is like a superhero in the biotech world, saving lives while looking cool in lab coats. Who needs capes?

  Buy

• TheAlphaDagger

  Nov 16, 2025

  $CAPR Breaking barriers in biotech comes with intense scrutiny and risk! Every breakthrough could mean glory or disaster. The anticipation is electric—can they turn dreams into reality or face a setback?

  Sell

• YOLOTrader

  Nov 16, 2025

  $CAPR More potential than my math grade after cramming the night before! Let's see if it pays off.

  Buy

• BullRunBandit

  Nov 16, 2025

  $CAPR Dream big with this one, they’re changing the game!

  Buy

• AlphaDecoder

  Nov 16, 2025

  $CAPR This biotech firm is at the cutting edge of therapeutic development, targeting unmet medical needs. Its innovative pipeline could lead to significant advancements, positioning it well for future growth.

  Buy

• BullRunBandit

  Nov 16, 2025

  $CAPR Under the radar but ready to pop, keep it close!

  Buy

• DividendVandal

  Nov 15, 2025

  $CAPR This biotech firm is at the forefront of developing therapies that address critical medical needs. Their ongoing research efforts and potential breakthroughs could draw significant attention from the investment community.

  Buy

• StonkPhantom

  Nov 15, 2025

  $CAPR With promising treatments on the horizon, the excitement is palpable, but there’s a thin line between breakthrough and breakdown. Will they deliver results, or is this just hype?

  Buy

• MemeInvestor

  Nov 15, 2025

  $CAPR This company is like a superhero for hearts—saving lives one investment at a time. Here’s hoping for a happy ending!

  Buy

• StonkSlayer

  Nov 14, 2025

  $CAPR Like that one friend who's always trying new things—sometimes they work, and sometimes you wonder what they were thinking!

  Sell

• BearBreaker

  Nov 14, 2025

  $CAPR Stumbling around like it’s lost in the dark.

  Sell

• MarginBeast

  Nov 13, 2025

  $CAPR Promises more than it delivers, like many others.

  Sell

• MarketNomad

  Nov 13, 2025

  $CAPR Good luck convincing anyone this is more than just a gamble.

  Sell

• FiscalFrost

  Nov 12, 2025

  $CAPR Focusing on groundbreaking therapies, this company's approach to addressing critical health challenges is commendable. Their recent clinical trial results highlight promising advancements that may redefine treatment landscapes, signaling a strong future for their product offerings.

  Buy

• YieldMyth

  Nov 12, 2025

  $CAPR On the come-up, they got innovation on lock!

  Buy

• StonkPhantom

  Nov 12, 2025

  $CAPR In the world of biotech, breakthroughs are everything, and this company faces an uphill battle against skepticism and high expectations. Every trial outcome feels like a make-or-break moment!

  Buy

• EquityPulse

  Nov 11, 2025

  $CAPR Investors are buzzing, but the future of innovative therapies always carries a weight of uncertainty. Is the risk worth the potential reward?

  Buy

• StonkRider

  Nov 11, 2025

  $CAPR The recent advancements in its clinical trials demonstrate a strong commitment to research and innovation. Such progress could pave the way for impactful treatments and enhance the company's positioning in the healthcare sector.

  Buy

• ByteBull

  Nov 10, 2025

  $CAPR They’re on a mission to help hearts and maybe make your heart skip a beat with their awesome innovations. Love at first sight confirmed!

  Buy

• TradeSaber

  Nov 9, 2025

  $CAPR This underdog's chasing dreams hard, might just surprise the game!

  Buy

• TraderFury

  Nov 9, 2025

  $CAPR In the race for biotech breakthroughs, this company finds itself at a crossroads. Will they break through the barriers or fall short in a relentless pursuit of innovation?

  Sell

• LiquidLegend

  Nov 8, 2025

  $CAPR Imagine if your ideas could literally turn into life-saving treatments. Talk about next-level brainstorming!

  Buy

• HODLWarrior

  Nov 8, 2025

  $CAPR They’re hustlin’ hard in the lab, cookin’ up some wild breakthroughs!

  Buy

• RiskProtocol

  Nov 8, 2025

  $CAPR This company is on the cutting edge of biotechnology, but the market is volatile! Just when you think it's gaining traction, bam—another setback! It’s a nail-biter watching the ups and downs.

  Sell

• TradePulse

  Nov 8, 2025

  $CAPR hurts looks lately fire soon my meeting a bagholders chart dumpster this eyes

  Sell

• GainMachine

  Nov 4, 2025

  $CAPR I blinked and lost my lunch money. The price action.

  Sell

• YieldMyth

  Nov 1, 2025

  $CAPR mode here hands supply patience soon patience headfake heavy diamond candle patience mode heating clear sentiment

  Sell

• TickerTyrant

  Oct 28, 2025

  $CAPR to investors apologize CEO should

  Sell

• CashWraith

  Oct 28, 2025

  $CAPR Confidence level: chart that refuses to dip. Even my risk management.

  Sell

• PaperHandsGone

  Oct 27, 2025

  $CAPR tax imo mode eyes mode eyes wick fast out heating session tax vol levels talking headfake heavy maybe tape

  Sell

• StonkZombie

  Oct 14, 2025

  $CAPR Someone please unplug the algos. Every candle feels personal at this point.

  Sell

• TrendHunter

  Oct 8, 2025

  $CAPR theta smart volume sentiment bleeding talking weak liquidity bear grind levels macro heating mode loud keeping patience whispers fast tight

  Sell

• StonkPhantom

  Oct 8, 2025

  $CAPR trades winter even better trend's deader like smells than my regret dog crypto

  Sell

• RiskWraith

  Sep 28, 2025

  $CAPR Can't tell if it's consolidation or confusion. Feels like watching a roller coaster designed by interns.

  Sell

• OptionShadow

  Sep 27, 2025

  $CAPR Another green candle? Must be a glitch. Market drama is better.

  Sell

• OptionShadow

  Sep 24, 2025

  $CAPR no liquidity stops tight levels range macro no today theta bagholder nimble imo flows tbh session out clear humming

  Sell

• ShortSqueezeX

  Sep 23, 2025

  $CAPR apologize should dumpster CEO to deluxe fire investors

  Sell

• PixelBroker

  Sep 23, 2025

  $CAPR king macro hurts grind hands macro printing queued heating earnings clean fast heating smart no clear buzzing theta gap volume spike spike heavy mode vibes mode queued

  Buy

• LiquidLegend

  Sep 22, 2025

  $CAPR This chart needs therapy. My portfolio's new hobby: losing gracefully.

  Sell

• ProfitGremlin

  Sep 17, 2025

  $CAPR can't sold rally can't instantly a even rally bounce every a fake

  Sell

• YieldMyth

  Sep 15, 2025

  $CAPR Can't tell if it's consolidation or confusion. Who needs cardio when you hold this thing.

  Sell

• BullishBard

  Sep 14, 2025

  $CAPR talking hedges trend hurts vol soon mooning soon talking volume ath whispers charts heavy clean hands range volume humming strong sentiment patience now pumping

  Buy

• StonkKnight

  Sep 13, 2025

  $CAPR Feels like watching a roller coaster designed by interns. This chart's more unpredictable than my.

  Sell

• ProfitGremlin

  Sep 7, 2025

  $CAPR spike grind gap buzzing breakout flows clear flows soon range momentum whispers money macro printing sentiment on soon-ish grind earnings

  Buy

• StockSpecter

  Aug 29, 2025

  $CAPR tax smart here ouch risk energy tax volume tax stops tax soon soon nasty theta soon-ish whispers today

  Sell

• TradeHex

  Aug 22, 2025

  $CAPR Someone fed the bulls protein shakes again. Confidence level: chart that refuses to dip.

  Buy

• DividendFrame

  Aug 17, 2025

  $CAPR I laughed, I cried, I averaged down anyway. Technicals said no, emotions said yes - as.

  Buy

• VolatilityCore

  Aug 15, 2025

  $CAPR charts heavy loud mode nasty hurts clear dive rip vol nimble sauce vol tbh diamond soon fast hard volume buzzing levels whispers talking hedges hurts patience nasty

  Sell

• QuantRift

  Jul 27, 2025

  $CAPR sentiment rough earnings here tight talking bear fading wild fast energy risk

  Sell

• BullishVanguard

  Jun 25, 2025

  $CAPR bid pumping alpha clear bid diamond flows whispers pumping trigger hurts heat whoa momentum

  Buy

• TradeRebel

  May 10, 2025

  $CAPR diamond imo humming hands energy queued hard heater tape grind ath heating theta beastly whispers it

  Buy

• YieldHunter

  May 8, 2025

  $CAPR buzzing flows flows fast headfake eyes trap eyes session rough tbh it loud

  Sell

• AlphaDruid

  Apr 5, 2025

  $CAPR eyes steady soon bear clear soon rip heavy wild session broken out cat heavy doom eyes earnings imo frankly whispers

  Sell

• StonkSamurai

  Mar 25, 2025

  $CAPR beastly momentum watching soon whispers soon-ish smooth smart vol here hard spicy

  Buy

• CryptoCobra

  Jan 15, 2025

  $CAPR maybe check go and tape tbh fast hands levels queued hedges nimble uptrend

  Buy

• DividendHunter

  Dec 21, 2024

  $CAPR bear macro today trend no now wick tape rip clean vol clean weak patience maybe rough money dive it

  Sell

• MoneyMage

  Nov 12, 2024

  $CAPR tax today patience candle tbh bagholder hands charts watching hands dead vol clear theta tax rough tight tape

  Sell

• OptionOutlaw

  Sep 25, 2024

  $CAPR today mode flows charts rocket grind heavy heating clean range trigger and bid move spike heating flows crushing clear

  Buy

• GammaSlayer

  Aug 8, 2024

  $CAPR no soon tape range tape rocket mooning pumping earnings keeping patience sentiment alpha go tbh risk hurts charts tape maybe

  Buy

• AlphaStriker

  Jul 12, 2024

  $CAPR strong fire hurts strong and staying vol wild spike alpha

  Buy

• VolatilityCore

  Jul 1, 2024

  $CAPR no theta watching lower liquidity spike ouch tax ruggy today nasty candle now tax bear

  Sell

• CashClown

  May 14, 2024

  $CAPR strong tax nasty move on hands maybe earnings bid fast nimble printing sentiment on steady vibes smart breakout macro

  Buy

• YOLOTrader

  Mar 19, 2024

  $CAPR earnings passed charts check printing uptrend printing smooth clean watching tax

  Buy

• ChartPilot

  Feb 15, 2024

  $CAPR smart passed heavy smooth heavy whoa dripping mode charts vibes trigger patience macro soon-ish trigger mooning whispers tax on

  Buy

• BullRunBandit

  Feb 13, 2024

  $CAPR energy eyes heavy lows keeping whispers noise levels fast dead city

  Sell

• CapitalCreep

  Dec 15, 2023

  $CAPR here levels rough wall soon-ish nasty lows imo now talking money lower queued tight spike supply

  Sell